Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice

Clinical and Experimental Rheumatology

Volumn 27, Issue 2, 2009, Pages 315-320

  Laas, K ^a   Peltomaa, R ^a   Puolakka, K ^b   Kautiainen, H ^c   Leirisalo Repo, M ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Lappeenranta Central Hospital   (Finland)

^c RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

Adalimumab; etanercept; HRQoL; RAND 36; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; GOLD SALT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PODOPHYLLOTOXIN; SALAZOSULFAPYRIDINE;

ADULT; ARTHRALGIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG EFFICACY; EMOTION; ENERGY; FEMALE; FINLAND; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SOCIAL INTERACTION; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 67449100311     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. LIPSKY PE. VAN DER HEIJDE DM. ST. CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000: 343: 1594-602.
2. MORELAND LW. BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fe fusion protein. N Engl J Med 1997:337: 141-7.
3. HAN C, SMOLEN J. KAVANAUGH A et al.: The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007: 9: Rl03.
4. MITTENDORF T. DIETZ B. STERZ R. KUPPER H. CIFALDI MA. VON DER SCHULENBURG JM: Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J Rheumatol 2007: 34: 2343-50.
5. FRIES JF: The assessment of disability: from first to future principles. Br J Rheumatol 1983; 22: 48-58.
6. HAYS RD. SHERBOURNE CD, MAZEL RM: The RAND 36-Item Health Survey 1.0. Health Econ 1993: 2: 2 17-27.
7. LINDE L, SORENSEN J, OSTERGAARD M. HORSLEV-PETERSEN K, HETLAND ML: Health-Related Quality of Life: Validity, Reliability, and Responsiveness of SF-36, EQ15D, EQ-5D, RAQoL, and HAQ in Patients with Rheumatoid Arthritis. J Rheumatol 2008: 35: 1482-3.
8. HAKALA M, NIEMINEN P. MANELIUS J: Joint impainnent is strongly correlated with disability measured by self-report questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population based series. J Rheumatol 1994: 21: 64-9.
9. AALTO AM, ARO AR, TEPERI J: RAND-36 as a measure of Health-Related Quality of Life. Reliability, construct validity and reference values in the Finnish general population (English summary). Helsinki: Stakes. Research reports 101.1999. ISBN 951-33-0827-8.
10. CARR AJ. THOMPSON PW, KIRWAN JR: Quality of life measures. Br J Rheumatol 1996: 35: 275-81.
11. GILL TM. FEINSTEIN AR: A critical appraisal of the quality of quality-of-life measurements. JAMA 1994: 272: 619-26.
12. STRAND V. SINGH JA: Improved health-related quality of life with effective disease.modifying antirheumatic drugs: evidence from randomized controlled trials. Ant J Manag Care 2007: 13 (Suppl. 9): S237-51.
13. WARE JE JR. SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992: 30:473-83.
14. MATHIAS SD. COLWELI. HH. MILLER DR MORELAND LW. BUATTI M. WANKE L: Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000: 22: 128-39.
15. MICHAUD K. BOMBARDIER C. EMERY P: Quality of life in patients with rheumatoid arthritis: Does abatacept make a difference? Clin Exp Rhemnatol 2007: 25 (Suppl. 46): S35-S45.
16. KOSINSKI M. ZI-IAO SZ. DEDHIYA S. OSTERHAUS JT. WARE JE JR: Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000: 43: 1478-87.
17. KOBELT G. EBERHARDT K. JONSSON I. JONSSON B: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999: 42.347-56.
18. KAVANAUGH A. HAN C. BALA M: Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rhewatol 2004: 31: 849-55.
19. KOBELT C: Health economic issues in rheumatoid arthritis. Scand J Rheunatol 2006: 35: 415-25.
20. KIMEL M, CIFALDt M, CHEN N. REVICKI D: Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on svork activity for patients with early RA. J Rheumatol 20008: 35: 206-15.
21. KIEVIT Vs. ADANG EM. -RANSEN J et al.: The effectiveness and medication costs of three anti-TNF agents{alpha} in the treatment of rheumatoid arthritis from prospective clinical practice data. Aizit Rheum Dis 2008: 67: 1229-34.
22. ROIJX CH. GUll LEMIN F. BOINI S et al.: Impact of musculoskeletal disorders on quality of life: an Inception cohort study. Ann Rheum Dis 2005: 64: 606-11.
23. PINCUS T. MACLEAN R. YAZICI Y. HARRINGTON JT: Quantitative measurement of patient status in the regular care of patients with rheumatic diseases over 25 years as a continuous quality improvement activity. rather than a traditional research. Clin Exp Rheumatol 2007:25 (Suppl. 47): S69-S8 I.